Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis

INTRODUCTION: Biologic therapies have improved the clinical management of ankylosing spondylitis (AS). Few head-to-head studies have directly compared the efficacy of these agents. This study was conducted to indirectly compare the efficacy of biologic agents for treatment of active AS. METHODS: A t...

Descripción completa

Detalles Bibliográficos
Autores principales: Betts, Keith A., Griffith, Jenny, Song, Yan, Mittal, Manish, Joshi, Avani, Wu, Eric Q., Ganguli, Arijit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127962/
https://www.ncbi.nlm.nih.gov/pubmed/27747581
http://dx.doi.org/10.1007/s40744-016-0038-y
_version_ 1782470313652518912
author Betts, Keith A.
Griffith, Jenny
Song, Yan
Mittal, Manish
Joshi, Avani
Wu, Eric Q.
Ganguli, Arijit
author_facet Betts, Keith A.
Griffith, Jenny
Song, Yan
Mittal, Manish
Joshi, Avani
Wu, Eric Q.
Ganguli, Arijit
author_sort Betts, Keith A.
collection PubMed
description INTRODUCTION: Biologic therapies have improved the clinical management of ankylosing spondylitis (AS). Few head-to-head studies have directly compared the efficacy of these agents. This study was conducted to indirectly compare the efficacy of biologic agents for treatment of active AS. METHODS: A targeted literature review was conducted to identify randomized clinical trials for adalimumab, infliximab, golimumab, certolizumab pegol, etanercept, and secukinumab for the treatment of active AS. The clinical efficacy was evaluated using ASAS20 and ASAS40 and synthesized via a Bayesian network meta-analysis. Number needed to treat (NNT) was calculated as the reciprocal of incremental response rate of each biologic versus placebo. Comparisons were also made in terms of cost per incremental ASAS20 or ASAS40 responder. RESULTS: Fifteen studies were identified, which included ASAS20 and/or ASAS40 response rates at Week 12 to Week 16. Patients with AS treated with infliximab had the lowest NNT for ASAS20 of 2.3, followed by those treated with adalimumab (2.8) and etanercept (2.9). Adalimumab had the lowest 12-week cost per additional ASAS20 responder at $26,888, followed by infliximab at $28,175 and golimumab at $28,199. Patients treated with infliximab also had the lowest NNT for ASAS40 (2.6), followed by those treated with adalimumab (2.8) and secukinumab (3.5). Adalimumab had the lowest cost per additional ASAS40 responder at $26,898, followed by infliximab at $32,508 and etanercept at $34,406. CONCLUSION: Infliximab had the lowest NNT to achieve an additional ASAS20/40 response, and adalimumab had the lowest cost per ASAS20/40 responder among biologic agents for the treatment of active AS. FUNDING: AbbVie.
format Online
Article
Text
id pubmed-5127962
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-51279622016-12-19 Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis Betts, Keith A. Griffith, Jenny Song, Yan Mittal, Manish Joshi, Avani Wu, Eric Q. Ganguli, Arijit Rheumatol Ther Original Research INTRODUCTION: Biologic therapies have improved the clinical management of ankylosing spondylitis (AS). Few head-to-head studies have directly compared the efficacy of these agents. This study was conducted to indirectly compare the efficacy of biologic agents for treatment of active AS. METHODS: A targeted literature review was conducted to identify randomized clinical trials for adalimumab, infliximab, golimumab, certolizumab pegol, etanercept, and secukinumab for the treatment of active AS. The clinical efficacy was evaluated using ASAS20 and ASAS40 and synthesized via a Bayesian network meta-analysis. Number needed to treat (NNT) was calculated as the reciprocal of incremental response rate of each biologic versus placebo. Comparisons were also made in terms of cost per incremental ASAS20 or ASAS40 responder. RESULTS: Fifteen studies were identified, which included ASAS20 and/or ASAS40 response rates at Week 12 to Week 16. Patients with AS treated with infliximab had the lowest NNT for ASAS20 of 2.3, followed by those treated with adalimumab (2.8) and etanercept (2.9). Adalimumab had the lowest 12-week cost per additional ASAS20 responder at $26,888, followed by infliximab at $28,175 and golimumab at $28,199. Patients treated with infliximab also had the lowest NNT for ASAS40 (2.6), followed by those treated with adalimumab (2.8) and secukinumab (3.5). Adalimumab had the lowest cost per additional ASAS40 responder at $26,898, followed by infliximab at $32,508 and etanercept at $34,406. CONCLUSION: Infliximab had the lowest NNT to achieve an additional ASAS20/40 response, and adalimumab had the lowest cost per ASAS20/40 responder among biologic agents for the treatment of active AS. FUNDING: AbbVie. Springer Healthcare 2016-07-25 /pmc/articles/PMC5127962/ /pubmed/27747581 http://dx.doi.org/10.1007/s40744-016-0038-y Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Betts, Keith A.
Griffith, Jenny
Song, Yan
Mittal, Manish
Joshi, Avani
Wu, Eric Q.
Ganguli, Arijit
Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
title Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
title_full Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
title_fullStr Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
title_full_unstemmed Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
title_short Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
title_sort network meta-analysis and cost per responder of tumor necrosis factor-α and interleukin inhibitors in the treatment of active ankylosing spondylitis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127962/
https://www.ncbi.nlm.nih.gov/pubmed/27747581
http://dx.doi.org/10.1007/s40744-016-0038-y
work_keys_str_mv AT bettskeitha networkmetaanalysisandcostperresponderoftumornecrosisfactoraandinterleukininhibitorsinthetreatmentofactiveankylosingspondylitis
AT griffithjenny networkmetaanalysisandcostperresponderoftumornecrosisfactoraandinterleukininhibitorsinthetreatmentofactiveankylosingspondylitis
AT songyan networkmetaanalysisandcostperresponderoftumornecrosisfactoraandinterleukininhibitorsinthetreatmentofactiveankylosingspondylitis
AT mittalmanish networkmetaanalysisandcostperresponderoftumornecrosisfactoraandinterleukininhibitorsinthetreatmentofactiveankylosingspondylitis
AT joshiavani networkmetaanalysisandcostperresponderoftumornecrosisfactoraandinterleukininhibitorsinthetreatmentofactiveankylosingspondylitis
AT wuericq networkmetaanalysisandcostperresponderoftumornecrosisfactoraandinterleukininhibitorsinthetreatmentofactiveankylosingspondylitis
AT ganguliarijit networkmetaanalysisandcostperresponderoftumornecrosisfactoraandinterleukininhibitorsinthetreatmentofactiveankylosingspondylitis